Combination of SMO inhibitor sonidegib with ruxolitinib showed ≥ 50% decrease in splenomegaly on clinical exam in 65% of MF patients, with 9 achieving CR (Gupta et al., 2014). The gene discussed is SMO; the disease is Splenomegaly.